Hook & thesis
BioMarin is a cash-flowing rare-disease biotech that looks mispriced for the next 12-18 months. The company has a cornerstone commercial -- VOXZOGO -- that generated $472 million in first-half 2026 sales and is on track for roughly $1.00-$1.05 billion for full-year 2026. At the same time, BioMarin turned a headwind into a monetization event: a royalty-bearing settlement on Ascendis Pharma's Yuviwel that yields material royalties through 05/2030. Those two developments, together with an active pipeline in Duchenne and Fabry disease, support meaningful upside to the stock from today's ~$64 trading level.
My trade thesis: buy BMRN now for a long-term swing into 2027. Near-term technical pressure and elevated short interest create volatility; that is an opportunity for disciplined buyers. The market is underappreciating recurring cash generation from VOXZOGO plus the non-dilutive royalty stream and the optionality embedded in late-stage pipeline programs. I see a path to $95 by 2027 if commercial momentum continues and pipeline readouts or approvals progress as expected.
Business snapshot - what BioMarin does and why the market should care
BioMarin is a rare-disease biotech focused on genetically defined conditions, with nine commercial therapies and a pipeline spanning enzyme replacement, gene therapy, and small molecules. The company is best known commercially for VOXZOGO, which has established blockbuster-scale revenues and should remain a durable cash generator if uptake and pricing sustain.
Why the market should care: VOXZOGO is already a billion-dollar franchise on a run-rate basis, and management has demonstrated an ability to convert clinical progress into label expansion. The firm also just converted a competitive threat into a royalty stream by settling a patent dispute with Ascendis - a structurally attractive, non-dilutive revenue line that improves visibility on near-term cash flows.
Key numbers backing the case
- Current price: $64.14 per share (recent snapshot).
- Market capitalization: roughly $12.4 billion.
- Enterprise value: ~$15.7 billion; EV/sales ~4.6x, EV/EBITDA ~51.4x.
- Free cash flow: $738 million (most recent reported FCF).
- P/E (trailing): ~170x, EPS $0.38 (reflects low trailing GAAP earnings relative to strong cash flow).
- VOXZOGO commercial performance: $472 million in H1 2026; guidance implies $1.00-$1.05 billion for 2026.
- 52-week range: $49.26 - $70.98.
Put differently, FCF of ~$738 million on a $12.4 billion market cap implies a FCF yield near 6%, which is attractive for a growth biotech with a clear blockbuster product and an added royalty stream. The high trailing P/E is a function of low GAAP earnings versus high investment and non-cash items common to biotechs; cast against cash generation and near-term commercial growth, the multiple looks more tolerable.
Valuation framing
At a $12.4 billion market cap and $15.7 billion EV, BioMarin trades at EV/sales around 4.6x and EV/EBITDA north of 50x. Those multiples are elevated versus mature pharma but reasonable for a company with a growing $1B+ franchise and ongoing optionality from late-stage programs. The stock has traded between the current $64 and its 52-week high of $70.98; downside to the 52-week low ($49.26) is possible if commercial momentum falters, but upside to the mid-$80s and beyond is realistic if VOXZOGO growth and royalty receipts accelerate.
Two valuation anchors matter here: (1) the magnitude and durability of VOXZOGO revenue (guidance ~ $1.0-$1.05B for 2026), and (2) the size and timing of royalty cash flows from the Ascendis settlement (20% U.S., 18% EU/Brazil/S. Korea through 05/2030). Add to that steady FCF generation and the company’s pipeline optionality. Together these create a path to mid-teens revenue growth and a multiple re-rating if clinical progress is sustained.
Catalysts to drive the trade
- VOXZOGO commercial momentum and label expansions - the company reported positive CANOPY-HCH-3 data and indicated a supplemental FDA submission process (data announced 05/21/2026).
- Royalty receipts from the Ascendis settlement reported on 09/03/2026 convert a competitor threat into recurring revenue.
- Progress in Duchenne and Fabry programs - multiple pipeline readouts and designations could unlock upside across 2026-2027.
- Potential M&A / strategic transactions - the market has shown that BioMarin is an active acquirer/partner, which could accelerate growth or enhance valuation.
Trade plan (actionable)
| Item | Details |
|---|---|
| Entry price | $64.00 |
| Target price | $95.00 |
| Stop loss | $52.00 |
| Trade direction | Long |
| Horizon | Long term (180 trading days) - allow time for sustained commercial uptake, royalty streams to manifest, and potential pipeline readouts. |
Rationale for horizon: the thesis rests on realized commercial growth and royalty monetization rather than a single short-dated binary. Expect volatility in the short term (10 trading days) and potential consolidation over the mid term (45 trading days). The 180-trading-day horizon gives time for sales cadence, royalty recognition, and at least one meaningful pipeline update or commercial datapoint that could re-rate the stock.
Risks and counterarguments
- Competition and market share erosion - Yuviwel (Ascendis) and other entrants like BridgeBio's candidate could take share or pressure pricing, reducing VOXZOGO upside.
- Regulatory / reimbursement risk - label expansions and payer coverage are critical. Slower reimbursement or narrower coverage could meaningfully lower realized revenues.
- Clinical risk across the pipeline - late-stage assets carry execution risk; negative readouts could reset sentiment and valuation.
- High trailing multiples and sentiment - P/E near ~170x and EV/EBITDA above 50x make the stock vulnerable to sentiment shifts and multiple compression if growth disappoints.
- Operational execution - commercial execution outside core markets, supply issues, or manufacturing disruptions could impact revenue trends.
Counterargument worth considering: short interest and recent bearish technical indicators suggest traders expect more downside or consolidation before upside. The MACD state is bearish and short-volume days have been large, which can amplify downdrafts. If VOXZOGO uptake slows materially, or royalty timing is delayed, the stock could revisit the low-$50s or lower. That is precisely why a stop at $52 is prudent and why this is a measured long rather than an all-in directional bet.
What would change my mind
I would downgrade this trade if any of the following occur: a material and sustained decline in VOXZOGO sales (sequential declines or clear share loss), the royalty settlement terms are delayed or result in lower-than-expected receipts, a negative late-stage DMD readout that meaningfully raises R&D overruns, or a broader market de-rating of growth biotechs that pushes multiples far below current levels without offsetting fundamental improvement.
Conclusion
BioMarin presents a buyable setup with a defined risk-management plan. The combination of a $1B-scale VOXZOGO franchise, non-dilutive royalty income from a competitor settlement, and a pipeline with late-stage optionality supports upside to my $95 target over a 180-trading-day horizon. Elevated short interest and tactical technical weakness create trading volatility, but they also offer an entry point for a disciplined long trade. If you believe in durable rare-disease demand and value non-dilutive monetization, this trade has an asymmetric reward profile—provided you manage downside with the stop and watch catalysts closely.
Trade plan recap: Buy at $64.00, target $95.00, stop loss $52.00, horizon long term (180 trading days).